Michael Povey

620 total citations
31 papers, 355 citations indexed

About

Michael Povey is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Michael Povey has authored 31 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 9 papers in Infectious Diseases and 8 papers in Health. Recurrent topics in Michael Povey's work include Virology and Viral Diseases (16 papers), Herpesvirus Infections and Treatments (12 papers) and Vaccine Coverage and Hesitancy (8 papers). Michael Povey is often cited by papers focused on Virology and Viral Diseases (16 papers), Herpesvirus Infections and Treatments (12 papers) and Vaccine Coverage and Hesitancy (8 papers). Michael Povey collaborates with scholars based in Belgium, United States and Czechia. Michael Povey's co-authors include Annette Lam, J.M. Olivares, Alice K. Jacobs, Joris Diels, Zhongyun Zhao, Ouzama Henry, Stéphane Carryn, Emmanuel Di Paolo, Paul Gillard and Roman Prymula and has published in prestigious journals such as The Journal of Infectious Diseases, The Lancet Infectious Diseases and Vaccine.

In The Last Decade

Michael Povey

30 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Povey Belgium	10	198	125	86	69	44	31	355
Cinzia Piovesan Italy	11	130 0.7×	21 0.2×	82 1.0×	208 3.0×	18 0.4×	17	422
Tonia Jones United States	7	153 0.8×	59 0.5×	46 0.5×	87 1.3×	3 0.1×	10	312
Carole Beaudoin Canada	7	172 0.9×	29 0.2×	19 0.2×	61 0.9×	2 0.0×	14	408
Carlos R. Oliveira United States	13	227 1.1×	30 0.2×	67 0.8×	68 1.0×	12 0.3×	51	392
Nora Dellepiane Switzerland	10	87 0.4×	11 0.1×	83 1.0×	101 1.5×	5 0.1×	18	249
Karen Bell United States	10	97 0.5×	31 0.2×	59 0.7×	72 1.0×	2 0.0×	15	328
Rujun Hu China	6	37 0.2×	17 0.1×	24 0.3×	89 1.3×	62 1.4×	22	266
Margaret Smith United States	7	100 0.5×	16 0.1×	13 0.2×	65 0.9×	9 0.2×	20	346
Valentine Wanga United States	10	108 0.5×	26 0.2×	6 0.1×	109 1.6×	5 0.1×	20	428

Countries citing papers authored by Michael Povey

Since Specialization

Citations

This map shows the geographic impact of Michael Povey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Povey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Povey more than expected).

Fields of papers citing papers by Michael Povey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Povey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Povey. The network helps show where Michael Povey may publish in the future.

Co-authorship network of co-authors of Michael Povey

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Povey. A scholar is included among the top collaborators of Michael Povey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Povey. Michael Povey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Povey, Michael, et al.. (2023). Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines. Human Vaccines & Immunotherapeutics. 19(1). 2188852–2188852. 2 indexed citations

Lau, YL, Ting Fan Leung, Benhur Şirvan Çetin, et al.. (2022). Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study. Vaccine. 40(14). 2184–2190. 3 indexed citations

Prymula, Roman, Michael Povey, Jerzy Brzostek, et al.. (2021). Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries. Vaccine. 39(19). 2643–2651. 10 indexed citations

Habib, Md. Ahsan, Roman Prymula, Stéphane Carryn, et al.. (2021). Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. Vaccine. 39(25). 3445–3454. 8 indexed citations

Povey, Michael, et al.. (2020). Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children. Vaccine. 38(17). 3300–3304. 5 indexed citations

Carryn, Stéphane, et al.. (2019). Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. Vaccine. 37(36). 5323–5331. 24 indexed citations

Friel, Damien, Emmanuel Di Paolo, Adrian Caplanusi, et al.. (2019). Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates. The Journal of Infectious Diseases. 220(9). 1462–1468. 8 indexed citations

Povey, Michael, Ouzama Henry, Marianne A. Riise Bergsaker, et al.. (2019). Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. The Lancet Infectious Diseases. 19(3). 287–297. 31 indexed citations

Faust, Saul N., Chitsanu Pancharoen, M Weber, et al.. (2019). Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. BMC Pediatrics. 19(1). 3 indexed citations

10.

Henry, Ouzama, Jerzy Brzostek, Hanna Czajka, et al.. (2017). One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine. 36(3). 381–387. 17 indexed citations

11.

Berry, Andrea A., Remon Abu‐Elyazeed, Maurice A. Mufson, et al.. (2017). Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin. Human Vaccines & Immunotherapeutics. 13(7). 1516–1522. 7 indexed citations

12.

Prymula, Roman, et al.. (2016). Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial. BMC Pediatrics. 16(1). 7–7. 7 indexed citations

13.

Durando, Paolo, Susanna Esposito, Gianni Bona, et al.. (2016). The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy. Vaccine. 34(36). 4278–4284. 9 indexed citations

14.

Lalwani, Sanjay, Sukanta Chatterjee, Sundaram Balasubramanian, et al.. (2015). Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. BMJ Open. 5(9). e007202–e007202. 15 indexed citations

15.

Mufson, Maurice A., Carlos Javier Gómez Díaz, M. Leonardi, et al.. (2014). Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months. Journal of the Pediatric Infectious Diseases Society. 4(4). 339–348. 15 indexed citations

16.

Cha, Sung‐Ho, et al.. (2014). Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children. Clinical and Experimental Vaccine Research. 3(1). 91–91. 8 indexed citations

17.

Huang, Li‐Min, et al.. (2013). Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore. Human Vaccines & Immunotherapeutics. 9(6). 1308–1315. 7 indexed citations

18.

Olivares, J.M., Joris Diels, Michael Povey, et al.. (2009). Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). European Psychiatry. 24(5). 287–296. 122 indexed citations

19.

Emmerson, Brett, et al.. (2007). PMH40 12-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI): INTERIM RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY PROJECT CONDUCTED IN SPAIN, AUSTRALIA AND BELGIUM. Value in Health. 10(3). A83–A83. 1 indexed citations

20.

Olivares, J.M., et al.. (2007). Reduced polypharmacy in patients enrolled in the electronic schizophrenia adherence registry (E-STAR) and treated with risperidone long-acting injection (RLAI) for 6 months. European Psychiatry. 22. S116–S117. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact